{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T00:23:23Z","timestamp":1792887803277,"version":"4.5.0"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejpn-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Paediatric Neurology"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.ejpn.2024.12.001","type":"journal-article","created":{"date-parts":[[2024,12,14]],"date-time":"2024-12-14T02:38:28Z","timestamp":1734143908000},"page":"42-49","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Efficacy and safety of Nusinersen among children with spinal muscular atrophy from North India: A prospective cohort study (NICE-SMA study)"],"prefix":"10.1016","volume":"54","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4243-749X","authenticated-orcid":false,"given":"Abhishek","family":"Pandey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4701-6168","authenticated-orcid":false,"given":"Renu","family":"Suthar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9989-307X","authenticated-orcid":false,"given":"Titiksha","family":"Sirari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manisha","family":"Malviya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3998-7143","authenticated-orcid":false,"given":"Somya","family":"Saxena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandhya","family":"Yaddanapudi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shobit","family":"Garg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arushi G.","family":"Saini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5194-9951","authenticated-orcid":false,"given":"Jitendra K.","family":"Sahu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naveen","family":"Sankhyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.ejpn.2024.12.001_bib1","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.ncl.2015.07.004","article-title":"Spinal muscular atrophy","volume":"33","author":"Kolb","year":"2015","journal-title":"Neurol. Clin."},{"issue":"1","key":"10.1016\/j.ejpn.2024.12.001_bib2","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/0092-8674(95)90460-3","article-title":"Identification and characterization of a spinal muscular atrophy-determining gene","volume":"80","author":"Lefebvre","year":"1995","journal-title":"Cell"},{"issue":"16","key":"10.1016\/j.ejpn.2024.12.001_bib3","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22169029","article-title":"The importance of digging into the genetics of SMN genes in the therapeutic scenario of spinal muscular atrophy","volume":"22","author":"Costa-Roger","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"4","key":"10.1016\/j.ejpn.2024.12.001_bib4","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0033572","article-title":"Evaluation of SMN protein, transcript, and copy number in the biomarkers for spinal muscular atrophy (BforSMA) clinical study","volume":"7","author":"Crawford","year":"2012","journal-title":"PLoS One"},{"issue":"15","key":"10.1016\/j.ejpn.2024.12.001_bib5","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1101\/gad.1941310","article-title":"Antisense correction of SMN2 splicing in the CNS rescues necrosis in a type III SMA mouse model","volume":"24","author":"Hua","year":"2010","journal-title":"Genes Dev."},{"issue":"3","key":"10.1016\/j.ejpn.2024.12.001_bib6","article-title":"The analysis of the association between the copy numbers of survival motor neuron gene 2 and neuronal apoptosis inhibitory protein genes and the clinical phenotypes in 40 patients with spinal muscular atrophy: observational study","volume":"99","author":"Zhang","year":"2020","journal-title":"Medicine (Baltim.)"},{"issue":"15","key":"10.1016\/j.ejpn.2024.12.001_bib7","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22157896","article-title":"Genomic variability in the survival motor neuron genes (SMN1 and SMN2): implications for spinal muscular atrophy phenotype and therapeutics development","volume":"22","author":"Butchbach","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejpn.2024.12.001_bib8","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2024.1308296","article-title":"The impact of three SMN2 gene copies on clinical characteristics and effect of disease-modifying treatment in patients with spinal muscular atrophy: a systematic literature review","volume":"15","author":"Dosi","year":"2024","journal-title":"Front. Neurol."},{"issue":"3","key":"10.1016\/j.ejpn.2024.12.001_bib9","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.nmd.2018.01.003","article-title":"Correlation between SMA type and SMN2 copy number revisited: an analysis of 625 unrelated Spanish patients and a compilation of 2834 reported cases","volume":"28","author":"Calucho","year":"2018","journal-title":"Neuromuscul. Disord."},{"issue":"10","key":"10.1016\/j.ejpn.2024.12.001_bib10","doi-asserted-by":"crossref","DOI":"10.3390\/brainsci13101446","article-title":"Pharmacological therapies of spinal muscular atrophy: a narrative review of preclinical, clinical-experimental, and real-world evidence","volume":"13","author":"Crisafulli","year":"2023","journal-title":"Brain Sci."},{"key":"10.1016\/j.ejpn.2024.12.001_bib11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejpn.2022.04.006","article-title":"Mid- and long-term (at least 12 months) follow-up of patients with spinal muscular atrophy (SMA) treated with nusinersen, onasemnogene abeparvovec, risdiplam or combination therapies: a systematic review of real-world study data","volume":"39","author":"Erdos","year":"2022","journal-title":"Eur. J. Paediatr. Neurol."},{"issue":"9","key":"10.1016\/j.ejpn.2024.12.001_bib12","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1038\/gt.2017.79","article-title":"Market access of Spinraza (Nusinersen) for spinal muscular atrophy: intellectual property rights, pricing, value and coverage considerations","volume":"24","author":"Simoens","year":"2017","journal-title":"Gene Ther."},{"issue":"18","key":"10.1016\/j.ejpn.2024.12.001_bib13","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","article-title":"Nusinersen versus sham control in infantile-onset spinal muscular atrophy","volume":"377","author":"Finkel","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.ejpn.2024.12.001_bib14","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1056\/NEJMoa1710504","article-title":"Nusinersen versus sham control in later-onset spinal muscular atrophy","volume":"378","author":"Mercuri","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"20","key":"10.1016\/j.ejpn.2024.12.001_bib15","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1212\/WNL.0000000000006502","article-title":"Evidence in focus: nusinersen use in spinal muscular atrophy: report of the guideline development, dissemination, and implementation subcommittee of the American Academy of Neurology","volume":"91","author":"Michelson","year":"2018","journal-title":"Neurology"},{"issue":"12","key":"10.1016\/j.ejpn.2024.12.001_bib16","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0278996","article-title":"Revised Hammersmith Scale for spinal muscular atrophy: inter and intra-rater reliability and agreement","volume":"17","author":"Ramsey","year":"2022","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.ejpn.2024.12.001_bib17","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1002\/mus.25430","article-title":"Revised upper limb module for spinal muscular atrophy: development of a new module","volume":"55","author":"Mazzone","year":"2017","journal-title":"Muscle Nerve"},{"issue":"3","key":"10.1016\/j.ejpn.2024.12.001_bib18","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1097\/BPO.0b013e31820fc522","article-title":"Development and initial validation of the assessment of caregiver experience with neuromuscular disease","volume":"31","author":"Matsumoto","year":"2011","journal-title":"J. Pediatr. Orthop."},{"issue":"2","key":"10.1016\/j.ejpn.2024.12.001_bib19","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.nmd.2017.11.005","article-title":"Diagnosis and management of spinal muscular atrophy: Part 1: recommendations for diagnosis, rehabilitation, orthopedic and nutritional care","volume":"28","author":"Mercuri","year":"2018","journal-title":"Neuromuscul. Disord."},{"issue":"3","key":"10.1016\/j.ejpn.2024.12.001_bib20","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.nmd.2017.11.004","article-title":"Diagnosis and management of spinal muscular atrophy: Part 2: pulmonary and acute care; medications, supplements and immunizations; other organ systems; and ethics","volume":"28","author":"Finkel","year":"2018","journal-title":"Neuromuscul. Disord."},{"issue":"12","key":"10.1016\/j.ejpn.2024.12.001_bib21","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1007\/s40263-021-00878-x","article-title":"Nusinersen: a review in 5q spinal muscular atrophy","volume":"35","author":"Hoy","year":"2021","journal-title":"CNS Drugs"},{"issue":"5","key":"10.1016\/j.ejpn.2024.12.001_bib22","doi-asserted-by":"crossref","DOI":"10.3390\/jcm12051920","article-title":"2-Year change in revised Hammersmith scale scores in a large cohort of untreated paediatric type 2 and 3 SMA participants","volume":"12","author":"Stimpson","year":"2023","journal-title":"J. Clin. Med."},{"issue":"1","key":"10.1016\/j.ejpn.2024.12.001_bib23","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1186\/s13023-023-02769-4","article-title":"Long-term nusinersen treatment across a wide spectrum of spinal muscular atrophy severity: a real-world experience","volume":"18","author":"Lusakowska","year":"2023","journal-title":"Orphanet J. Rare Dis."},{"issue":"9","key":"10.1016\/j.ejpn.2024.12.001_bib24","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1007\/s40263-019-00656-w","article-title":"An integrated safety analysis of infants and children with symptomatic spinal muscular atrophy (SMA) treated with nusinersen in seven clinical trials","volume":"33","author":"Darras","year":"2019","journal-title":"CNS Drugs"},{"issue":"2","key":"10.1016\/j.ejpn.2024.12.001_bib25","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1002\/mus.26769","article-title":"Nusinersen for older patients with spinal muscular atrophy: a real-world clinical setting experience","volume":"61","author":"Veerapandiyan","year":"2020","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.ejpn.2024.12.001_bib26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejpn.2020.11.004","article-title":"Children and young adults with spinal muscular atrophy treated with nusinersen","volume":"30","author":"Osredkar","year":"2021","journal-title":"Eur. J. Paediatr. Neurol."},{"issue":"21","key":"10.1016\/j.ejpn.2024.12.001_bib27","doi-asserted-by":"crossref","first-page":"e2492","DOI":"10.1212\/WNL.0000000000007527","article-title":"Nusinersen in later-onset spinal muscular atrophy: long-term results from the phase 1\/2 studies","volume":"92","author":"Darras","year":"2019","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.ejpn.2024.12.001_bib28","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1002\/mus.26633","article-title":"Nusinersen improves walking distance and reduces fatigue in later-onset spinal muscular atrophy","volume":"60","author":"Montes","year":"2019","journal-title":"Muscle Nerve"},{"issue":"8","key":"10.1016\/j.ejpn.2024.12.001_bib29","doi-asserted-by":"crossref","DOI":"10.3390\/jcm12082839","article-title":"Effectiveness of nusinersen in type 1, 2 and 3 spinal muscular atrophy: Croatian real-world data","volume":"12","author":"Belancic","year":"2023","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.ejpn.2024.12.001_bib30","first-page":"1","article-title":"Safety and effectiveness of nusinersen, a treatment for spinal muscular atrophy, in 524 patients: results from an interim analysis of post-marketing surveillance in Japan","author":"Tachibana","year":"2023","journal-title":"Int. J. Neurosci."},{"key":"10.1016\/j.ejpn.2024.12.001_bib31","article-title":"Determining minimal clinically important differences in the Hammersmith Functional Motor Scale Expanded for untreated spinal muscular atrophy patients: an international study","author":"Coratti","year":"2024","journal-title":"Eur. J. Neurol."},{"issue":"1","key":"10.1016\/j.ejpn.2024.12.001_bib32","doi-asserted-by":"crossref","first-page":"109","DOI":"10.3233\/JND-180342","article-title":"Perceived fatigue in spinal muscular atrophy: a pilot study","volume":"6","author":"Dunaway","year":"2019","journal-title":"J. Neuromuscul. Dis."},{"issue":"1","key":"10.1016\/j.ejpn.2024.12.001_bib33","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1002\/mus.27831","article-title":"Translating fatigability in spinal muscular atrophy to clinical trials and management","volume":"68","author":"Yeo","year":"2023","journal-title":"Muscle Nerve"},{"issue":"6","key":"10.1016\/j.ejpn.2024.12.001_bib34","doi-asserted-by":"crossref","first-page":"fcac269","DOI":"10.1093\/braincomms\/fcac269","article-title":"Population-based assessment of nusinersen efficacy in children with spinal muscular atrophy: a 3-year follow-up study","volume":"4","author":"Scheijmans","year":"2022","journal-title":"Brain Commun"},{"issue":"1","key":"10.1016\/j.ejpn.2024.12.001_bib35","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1186\/s13023-022-02547-8","article-title":"Improved upper limb function in non-ambulant children with SMA type 2 and 3 during nusinersen treatment: a prospective 3-years SMArtCARE registry study","volume":"17","author":"Pechmann","year":"2022","journal-title":"Orphanet J. Rare Dis."},{"issue":"5","key":"10.1016\/j.ejpn.2024.12.001_bib36","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1002\/mus.27187","article-title":"Safety and efficacy of nusinersen in spinal muscular atrophy: the EMBRACE study","volume":"63","author":"Acsadi","year":"2021","journal-title":"Muscle Nerve"}],"container-title":["European Journal of Paediatric Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1090379824001879?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1090379824001879?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T17:38:47Z","timestamp":1762364327000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1090379824001879"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":36,"alternative-id":["S1090379824001879"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpn.2024.12.001","relation":{},"ISSN":["1090-3798"],"issn-type":[{"value":"1090-3798","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of Nusinersen among children with spinal muscular atrophy from North India: A prospective cohort study (NICE-SMA study)","name":"articletitle","label":"Article Title"},{"value":"European Journal of Paediatric Neurology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpn.2024.12.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 European Paediatric Neurology Society. Published by Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}